Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy

Journal of Immunotherapy

Volumn 32, Issue 9, 2009, Pages 932-940

  Brestrich, Gordon ^a   Zwinger, Sandra ^a   Roemhild, Andy ^a   Noutsias, Michel ^a   Rohde, Maria ^a   Keeren, Kathrin ^a   Sawitzki, Birgit ^a   Volk, Hans Dieter ^a   Reinke, Petra ^a   Hammer, Markus H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adoptive T cell therapy; Cytomegalovirus; Posttransplant complication; Solid organ transplantation

Indexed keywords

EPITOPE; GAMMA INTERFERON; IMMEDIATE EARLY PROTEIN; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GENE EXPRESSION; GOOD MANUFACTURING PRACTICE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; ORGAN TRANSPLANTATION; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPE MAPPING; GENE EXPRESSION PROFILING; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION;

EID: 70350560649     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181b88fda     Document Type: Article

References (50)

1. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis. 2001;184:1461-1464.
2. Rubin RH. Cytomegalovirus in solid organ transplantation. Transpl Infect Dis. 2001;3(suppl 2):1-5.
3. Reinke P, Prosch S, Kern F, et al. Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transpl Infect Dis. 1999;1:157-164.
4. Cainelli F, Vento S. Infections and solid organ transplant rejection: a cause-and-effect relationship? Lancet Infect Dis. 2002;2:539-549.
5. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA. 1989;261: 3607-3609.
6. Walker RC, Marshall WF, Strickler JG, et al. Pretransplanta-tion assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 1995;20:1346-1353.
7. Reinke P, Fietze E, Ode-Hakim S, et al. Late-acute renal allograft rejection and symptom less cytomegalovirus infection. Lancet. 1994;344(8939-8940):1737-1738.
8. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002;35:866-872.
9. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000;356:645-649.
10. Reusser P, Riddell SR, Meyers JD, et al. Cytotoxic T-lympho-cyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78: 1373-1380.
11. Rauser G, Einsele H, Sinzger C, et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood. 2004;103:3565-3572.
12. Einsele H, Rauser G, Grigoleit U, et al. Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide. Cytotherapy. 2002;4:49-54.
13. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
14. Amrolia PJ, Muccioli-Casadei G, Yvon E, et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003;102:2292-2299.
15. Hammer MH, Meyer S, Brestrich G, et al. HLA type-independent generation of antigen-specific T cells for adoptive immuno-therapy. Eur J Immunol. 2005;35:2250-2258.
16. Roden MM, Lee KH, Panelli MC, et al. A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology. J Immunol Methods. 1999;226(1-2):29-41.
17. Kern F, Surel IP, Brock C, et al. T-cell epitope mapping by flow cytometry. Nat Med. 1998;4:975-978.
18. Block A, Rohde M, Erben U, et al. Impact of cell culture media on the expansion efficiency and T-cell receptor Vbeta (TRBV) repertoire of in vitro expanded T cells using feeder cells. Med Sci Monit. 2008;14:BR88-BR95.
19. Noutsias M, Rohde M, Block A, et al. Preamplification techniques for real-time RT-PCR analyses of endomyocardial biopsies. BMC Mol Biol. 2008;9:3.
20. Streitz M, Noutsias M, Volkmer R, et al. NS1 specific CD8+ T-cells with effector function and TRBV11 dominance in a patient with parvovirus B19 associated inflammatory cardio-myopathy. PLoS One. 2008;3:e2361.
21. Nalimov VV. The Application of Mathematical Statistics to Chemical Analysis. Oxford, England: Pergamon Press; 1963: 294-295.
22. Esser MT, Krishnamurthy B, Braciale VL. Distinct T cell receptor signaling requirements for perforin-or FasL-mediated cytotoxicity. J Exp Med. 1996;183:1697-1706.
23. Gamadia LE, Rentenaar RJ, Baars PA, et al. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. Blood. 2001;98:754-761.
24. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8:379-385.
25. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8:247-258.
26. Casazza JP, Betts MR, Price DA, et al. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med. 2006;203:2865-2877.
27. Nebbia G, Mattes FM, Smith C, et al. Polyfunctional cyto-megalovirus- specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am J Transplant. 2008;8:2590-2599.
28. Ho WY, Yee C, Greenberg PD. Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest. 2002;110:1415-1417.
29. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:238-241.
30. Brenchley JM, Karandikar NJ, Betts MR, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood. 2003;101:2711-2720.
31. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
32. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118:294-305.
33. Brestrich G, Zwinger S, Fischer A, et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant. 2009;9: 1679-1684. Epub 2009 May 20.
34. Prod'homme V, Retiere C, Imbert-Marcille BM, et al. Modulation of HLA-A*0201-restricted T cell responses by natural polymorphism in the IE1(315-324) epitope of human cytome-galovirus. J Immunol. 2003;170:2030-2036.
35. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202: 379-386.
36. Watanabe N, Kamachi Y, Koyama N, et al. Expansion of human CMV-specific cytotoxic T lymphocytes to a clinical scale: a simple culture system using tetrameric HLA-peptide complexes. Cytotherapy. 2004;6:514-522.
37. Fletcher JM, Vukmanovic-Stejic M, Dunne PJ, et al. Cyto-megalovirus- specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion. J Immunol. 2005; 175:8218-8225.
38. Ouyang Q, Wagner WM, Wikby A, et al. Large numbers of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. J Clin Immunol. 2003;23:247-257.
39. Pawelec G, Gouttefangeas C. T-cell dysregulation caused by chronic antigenic stress: the role of CMV in immunosenes-cence? Aging Clin Exp Res. 2006;18:171-173
40. Malignant glioma: clinical and experimental studies. Neurol Res. 1986;8:81-87.
41. Jacobs SK, Wilson DJ, Kornblith PL, et al. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res. 1986;46:2102-2104.
42. Yoshida S, Tanaka R, Takai N, et al. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res. 1988;48:5011-5016. (Pubitemid 18224469)
43. Merchant RE, Grant AJ, Merchant LH, et al. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer. 1988;62:665-671.
44. Barba D, Saris SC, Holder C, et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg. 1989;70:175-182.
45. Lillehei KO, Mitchell DH, Johnson SD, et al. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurg. 1991; 28:16-23.
46. Hayes RL, Koslow M, Hiesiger EM, et al. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer. 1995;76:840-852.
47. Dillman RO, Duma CM, Schiltz PM, et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother. 2004;27:398-404.
48. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79-88.
49. Pan E, Mitchell SB, Tsai JS. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol. 2008;88:353-357.
50. McVicar DW, Merchant RE, Merchant LH, et al. Corticoster-oids inhibit the generation of lymphokine-activated killer activity in vitro. Cancer Immunol Immunother. 1989;29: 211-218.